For the Inventor, By the Inventor

Enter assignee name

Boston, MA, United States of America

Decibel Therapeutics, Inc.

USPTO Granted Patents = 14

EPO Patents = 1

Trademarks = 5

Forward Citations = 20

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

Fuxin Shi (7 out of 9 patents)

Adam Palermo (7 out of 13 patents)

Joseph Burns (7 out of 8 patents)

4. Qi-Ying Hu (6 out of 33 patents)

5. John Lee (6 out of 66 patents)

6. Kathryn Ellis (6 out of 7 patents)

7. Martin Schwander (6 out of 7 patents)

8. Jonathon Whitton (5 out of 6 patents)

9. John R Soglia (3 out of 3 patents)

10. Christos Kyratsous (2 out of 41 patents)

11. Meghan Drummond Samuelson (2 out of 8 patents)

12. Leah Sabin (2 out of 5 patents)

13. Albert Edge (1 out of 31 patents)

14. Michael Venuti (1 out of 1 patent)

15. Agnieszka Czechowicz (1 out of 5 patents)

14 patents: Sort by Forward Citations

1. 12741034 - COMPOSITIONS AND METHODS FOR TREATING SENSORINEURAL HEARING LOSS USING OTOFERLIN DUAL VECTOR SYSTEMS (2026-09-22),

2. 12653838 - Methods of otoprotection against platinum-based antineoplastic agents (2026-06-16),

3. 12545930 - COCHLEAR INNER HAIR CELL PROMOTERS AND USES THEREOF (2026-02-10),

4. 12534739 - AAV1 VECTORS AND USES THEREOF FOR TREATMENT OF OTIC INDICATIONS (2026-01-27),

5. 12410442 - Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems (2025-09-09),

6. 12252520 - Myosin 15 promoters and uses thereof (2025-03-18),

7. 12233136 - Myosin 15 promoters and uses thereof (2025-02-25),

8. 11857567 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2024-01-02),

9. 11690870 - Methods of otoprotection against platinum-based antineoplastic agents (2023-07-04),

10. 11660353 - Compositions and methods for treating sensorineural hearing loss using otoferlin dual vector systems (2023-05-30),

11. 11466252 - Expansion and differentiation of inner ear supporting cells and methods of use thereof (2022-10-11),

12. 11071751 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2021-07-27),

13. 10813947 - Methods of otoprotection against platinum-based antineoplastic agents (2020-10-27),

14. 10709732 - Hypertonic pharmaceutical compositions containing an anti-platinum chemoprotectant agent (2020-07-14),

Company Overview

Decibel Therapeutics, Inc. is a biotechnology company based in Boston, MA, focused on developing innovative therapies for hearing and balance disorders. The organization specializes in harnessing advanced genetic and molecular technologies to create treatments aimed at restoring and preserving auditory function. With a commitment to addressing unmet medical needs in the field of otology, Decibel Therapeutics is at the forefront of research that seeks to transform the lives of individuals affected by hearing loss and related conditions.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

14 Patents

#151 in Boston, MA

#1,359 in Massachusetts

#22,302 in US

#42,199 in the World

Boston, MA, United States of America

Decibel Therapeutics, Inc.

Forward Citations = 20

19 inventors:

Fuxin Shi (7 out of 9 patents)

Adam Palermo (7 out of 13 patents)

Joseph Burns (7 out of 8 patents)

4. Qi-Ying Hu (6 out of 33 patents)

5. John Lee (6 out of 66 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Decibel Therapeutics, Inc.. Retrieved from https://idiyas.com/company/decibel-therapeutics

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…